XML 26 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) - USD ($)
Total
Conversion of Convertible Debt
Common Stock
Common Stock
Conversion of Convertible Debt
Treasury Stock
Additional Paid-in Capital
Additional Paid-in Capital
Conversion of Convertible Debt
Accumulated Other Comprehensive Loss
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2023     9,603,723            
Beginning balance at Dec. 31, 2023 $ 11,373,000   $ 96,000   $ (150,000) $ 153,827,000   $ (197,000) $ (142,203,000)
Treasury stock, beginning balance (in shares) at Dec. 31, 2023         (14,455)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock, net of issuance costs (in shares)     615,363            
Issuance of common stock, net of issuance costs 5,062,000   $ 6,000     5,056,000      
Issuance of common stock upon settlement of restricted stock (in shares)     903            
Issuance of common stock upon the exercise of common warrants 11,000         11,000      
Stock-based compensation 324,000         324,000      
Foreign currency translation adjustment (73,000)             (73,000)  
Net loss (11,827,000)               (11,827,000)
Balance at end of period (in shares) at Mar. 31, 2024     10,219,989            
Ending balance at Mar. 31, 2024 $ 4,870,000   $ 102,000   $ (150,000) 159,218,000   (270,000) (154,030,000)
Treasury stock, ending balance (in shares) at Mar. 31, 2024         (14,455)        
Balance at beginning of period (in shares) at Dec. 31, 2024 11,029,382   11,043,837            
Beginning balance at Dec. 31, 2024 $ (11,312,000)   $ 110,000   $ (150,000) 183,004,000   (175,000) (194,101,000)
Treasury stock, beginning balance (in shares) at Dec. 31, 2024 (14,455)       (14,455)        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock, net of issuance costs (in shares)     106,823            
Issuance of common stock, net of issuance costs $ 835,000   $ 1,000     834,000      
Exercise of stock options (in shares) 1,628   1,628            
Issuance of common stock upon exercise of options $ 7,000         7,000      
Conversion of senior note payable into common stock (in shares)       3,500,573          
Conversion of senior note payable into common stock   $ 20,176,000   $ 35,000     $ 20,141,000    
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants (in shares)     $ 1,261,830            
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants 9,143,000   $ 13,000     9,130,000      
Issuance of common stock upon settlement of restricted stock (in shares)     68,500            
Issuance of common stock upon the exercise of common warrants 716,000   $ 1,000     715,000      
Stock-based compensation 517,000         517,000      
Foreign currency translation adjustment 31,000             31,000  
Net loss $ (11,209,000)               (11,209,000)
Balance at end of period (in shares) at Mar. 31, 2025 15,968,736   15,983,191            
Ending balance at Mar. 31, 2025 $ 8,904,000   $ 160,000   $ (150,000) $ 214,348,000   $ (144,000) $ (205,310,000)
Treasury stock, ending balance (in shares) at Mar. 31, 2025 (14,455)       (14,455)